.png)
One Technology, Two Jobs: A New Approach to Cancer Care
What if one technology could help doctors find cancer and treat it using a targeted approach? That is the idea behind radiotheranostics. In cancer care it combines two important steps: diagnosis and treatment. Doctors start by using special radioactive substances to locate the cancer cells and determine their appearance. Then they can employ related substances to deliver treatment directly to the cells. This is transforming how doctors treat some cancers. The demand for better cancer treatment is growing and radiotheranostics is a trending topic in modern oncology.
What Is Radiotheranostics?
Radiotheranostics combines cancer diagnosis and treatment using radioactive substances called radionuclides. These substances are linked to molecules that recognize specific targets on cancer cells.
The process has two main steps. First, doctors use a diagnostic substance to locate cancer cells through medical imaging. This helps them understand where the cancer is present. Next, a therapeutic substance targets the same or a related marker and delivers radiation to the cancer cells.
The approach could help doctors select patients who are likely to respond to a specific treatment and monitor the response to therapy. Radiotheranostics aims to deliver radiation more directly to cancer cells than other therapies that impact a larger area but healthy tissue can still be affected and side effects may develop.
Key Growth Drivers
The growing need for targeted cancer treatment is creating interest in radiotheranostics. The field is progressing with the approval of new cancer diagnostics and treatments.
Targeted Radionuclide Therapy Approvals
New treatment approvals are supporting radiotheranostics reach more patients. Key examples include drugs such as Pluvicto for prostate cancer treatment and Lutathera for certain neuroendocrine tumors. These therapies deliver radiation to cancer cells with specific molecular targets. Their development has also encouraged the development of new radiopharmaceuticals for other cancers. With more treatments in clinical trials and gaining regulatory approval, doctors may have more options for patients who meet the criteria. This momentum is fueling interest in targeted radionuclide therapy.
Precision Oncology Demand
Cancer does not behave the same way in every patient. Even tumors in the same organ can have different characteristics. This is why doctors look more and more at the specific features of a patient's cancer when they are deciding how to treat it. Radiotheranostics supports identify tumors with certain molecular targets and assess whether a targeted therapy may be suitable. It also allows doctors to use imaging to examine treatment response. For the radiotheranostics market growing interest in personalized medicine, better imaging techniques, and research into new cancer targets is creating opportunities. These developments are also supporting the wider use of theranostics oncology.
Clinical Applications in Oncology
Radiotheranostics is used to treat certain cancers, particularly prostate cancer and neuroendocrine tumors.
Prostate cancer: Some advanced prostate cancers have a protein called PSMA on their cells. Radiotheranostics can target this protein and deliver radiation to the cancer cells. Doctors can also use PSMA-based imaging to see if a patient might be a candidate for treatment.
Neuroendocrine tumors: Some of these tumors carry somatostatin receptors. To locate tumors and deliver treatment radiopharmaceuticals can target these receptors.
Other cancers: Researchers are studying radiotheranostic treatments for other cancer types. These include approaches that target proteins such as FAP and HER2.
The treatment depends on the type of cancer, the presence of specific targets and the patient’s overall condition. In the coming years further research may widen its use.
Adoption Barriers
Radiotheranostics offers new treatment options, but some challenges can limit its use.
Radioisotope supply: Radioactive materials need careful handling and timely delivery. Some isotopes lose their radioactivity quickly, making production, storage, and transportation difficult. Supply shortages can affect treatment schedules.
Specialized facilities: Radiotheranostics requires trained medical professionals, suitable equipment, and proper radiation safety measures. Not every hospital has the facilities needed to provide these treatments.
Treatment costs and reimbursement: The cost of radiopharmaceuticals, scans, and specialized care can be high. Across regions insurance coverage and reimbursement policies also differ. For some patients this can make treatment difficult to access.
For more wider adoption, improving isotope production, expanding hospital facilities, training healthcare professionals and clarifying reimbursement policies will be important.
Market Outlook, 2026–2034
The radiotheranostics market is expected to grow as more hospitals adopt targeted cancer treatments and researchers develop new therapies. According to Polaris Market Research, the global radiotheranostics market was valued at USD 10.80 billion in 2025. It is projected to reach USD 24.21 billion by 2034, growing at a CAGR of 9.4% from 2026 to 2034.
The increasing use of radioligand therapies, the rising demand for customized cancer care, and investments in radiopharmaceutical manufacturing are driving market growth. Research on new radioisotopes, such as Actinium-225, is also opening up opportunities for future treatments. However, on several factors market growth will depend. These include clinical trial results, regulatory approvals, availability of radioactive materials and access to specialized healthcare facilities. The cost of treatment will also impact adoption across various regions.
FAQs
What is radiotheranostics?
Radiotheranostics combines cancer imaging and targeted radiation therapy to help doctors detect and treat cancer cells.
How is radiotheranostics different from traditional cancer imaging?
Traditional imaging detects tumors, while radiotheranostics combines imaging with targeted treatment.
Which cancers is radiotheranostics used for today?
It is used for certain prostate cancers and neuroendocrine tumors. Researchers are also studying its use in other cancers.
Conclusion
Radiotheranostics is creating new ways to find and treat cancer using a targeted approach. But there are still barriers to overcome like the cost of treatment and availability of isotopes. But research continues to expand its possibilities. As it progresses, it may provide more options for patients who need personalized cancer treatment.
Polaris Market Research’s Radiotheranostics Market Report provides insights on the market size, growth trends, emerging opportunities, and key industry developments.
